Journal article
The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada
Abstract
Background and ObjectiveAxicabtagene ciloleucel (axi-cel) received marketing authorisation in Canada for the treatment of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and the clinical and economic value of axi-cel to patients and the healthcare system should be examined. The objective of this analysis is to determine, from societal and public healthcare payer perspectives, the cost effectiveness of …
Authors
Hillis C; Vicente C; Ball G
Journal
PharmacoEconomics, Vol. 40, No. 9, pp. 917–928
Publisher
Springer Nature
Publication Date
9 2022
DOI
10.1007/s40273-022-01169-z
ISSN
1170-7690